title: [Efficacy of activated lymphocytes transfer therapy as a novel maker for serum granulysin level with advanced gastric cancer patients].
abstract: BACKGROUND
  Granulysin is a cytotoxic granule protein of cytotoxic T-lymphocytes and natural killer cells. Gastric cancer patients of stage II and stage III were reported to have pre-operative serum granulysin, which is a good prognostic factor. Activated T lymphocytes produce a lot of granulysin in the cell. We hypothesized that activated T lymphocytes transfer therapy may increase in serum granulysin leveles of stage IV and relapsed patients.
  
  
  METHODS
  Between April 2002 and December 2007, the patients received a standard therapy with activated lymphocytes transfer therapy. Peripheral blood samples were taken from the patients. Serum granulysin concentrations were measured using a granulysin-specific ELISA kit.
  
  
  RESULTS
  The average serum granulysin level for Stage IV (n=29) and relapsed patients (n=13) was 3.3 ng/mL. The gastric cancer patients were classified into two groups based on their concentration of serum granulysin level: high group (> or = 3.3 ng/mL); low group (< 3.3 ng/mL). There were no significant differences between these two groups in gender and age. The stage IV high group had a longer survival time than the stage IV low group. After 60 days from the activated T lymphocytes transfer therapy, the average pre-treatment serum granulysin had increased. However, there was no significant difference to note. It is noteworthy that serum granulysin is a novel parameter of patients cancer immunity.
authors.affiliation: Shinyokohama Kato Clinic.
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Kato
authors.forename: Jong-Chol
authors.initials: JC
authors.lastname: Cyon
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Yoshimatsu
authors.forename: Kenji
authors.initials: K
authors.lastname: Ogawa
mesh_terms: D000945:Antigens, Differentiation, T-Lymphocyte / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D006801:Humans; D007167:Immunotherapy; D008113:Liver Neoplasms / Q000097:blood / Q000276:immunology / Q000556:secondary / Q000628:therapy; D008213:Lymphocyte Activation / Q000276:immunology*; D017710:Lymphocyte Transfusion; D008214:Lymphocytes / Q000276:immunology*; D009367:Neoplasm Staging; D013274:Stomach Neoplasms / Q000097:blood / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate
chemical_list: D000945:Antigens, Differentiation, T-Lymphocyte; D015415:Biomarkers; C075005:GNLY protein, human